Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 8/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19327436 | 0.91 | POLB (0.56) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19327476 | 0.89 | POLB (0.56) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19327439 | 0.89 | POLB (0.58) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19327460 | 0.89 | POLB (0.58) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19327437 | 0.88 | POLB (0.69) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19327466 | 0.88 | POLB (0.66) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19327471 | 0.88 | LMNA (0.59) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL17609490 | 0.87 | MAPT (0.60) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19327425 | 0.87 | POLB (0.66) | POLBMEN1KMT2ANPC1RAB9A | |
| SCHEMBL19327428 | 0.85 | POLB (0.54) | POLBMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | PÉCSI TUDOMÁNYEGYETEM (HU) | 2019-07-09 | — | — | US | claimed |
| EP-3194399-B1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PECSI TUDOMANYEGYETEM (HU) | 2019-04-10 | — | — | EP | claimed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | claimed |
| EP-3194399-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | Pécsi Tudományegyetem (HU) | 2017-07-26 | — | — | EP | claimed |
| WO-2016042349-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2016-03-24 | — | — | WO | claimed |
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | PÉCSI TUDOMÁNYEGYETEM (HU) | 2019-07-09 | — | — | US | disclosed |
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | PÉCSI TUDOMÁNYEGYETEM (HU) | 2019-07-09 | — | — | US | disclosed |
| EP-3194399-B1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PECSI TUDOMANYEGYETEM (HU) | 2019-04-10 | — | — | EP | disclosed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | disclosed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | disclosed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | TRPV1, P2RX3, P2RX7 | POLB 3543/4885MEN1 4876/4885KMT2A 3460/4885 |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | TRPV1, P2RX3, P2RX4 | POLB 4002/4885MEN1 4866/4885KMT2A 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.